Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 6/20 | 0.62 |
| ▸ | HTR1D | P28221 | 6/20 | 0.62 |
| ▸ | HTR1B | P28222 | 6/20 | 0.62 |
| ▸ | HTR2C | P28335 | 4/20 | 0.62 |
| ▸ | HTR6 | P50406 | 3/20 | 0.62 |
| ▸ | HTR2A | P28223 | 2/20 | 0.62 |
| ▸ | HTR7 | P34969 | 2/20 | 0.62 |
| ▸ | DRD2 | P14416 | 1/20 | 0.58 |
| ▸ | DRD3 | P35462 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL314504 | 0.84 | GAA (0.68) | RAB9AGAAALDH1A1KDM4EP2RX4 | |
| SCHEMBL314528 | 0.84 | P2RX4 (0.55) | HTR1AHTR1DHTR1BHTR2CHTR6 | |
| SCHEMBL4978037 | 0.81 | RAB9A (0.52) | HTR1AHTR7DRD2HTTRAB9A | |
| SCHEMBL20140998 | 0.80 | MCOLN2 (0.55) | HTR1AHTR1DHTR1BHTR2CDRD2 | |
| SCHEMBL5457650 | 0.79 | DRD2 (0.77) | HTR1AHTR1DHTR1BHTR2CHTR6 | |
| SCHEMBL8759779 | 0.77 | HTR1A (1.00) | HTR1AHTR1DHTR1BHTR2CHTR6 | |
| SCHEMBL4865490 | 0.77 | TSHR (0.64) | LMNAMAPTRAB9AGAANPC1 | |
| SCHEMBL5748950 | 0.76 | MEN1 (0.50) | HTR2ADRD2LMNAHTTMAPT | |
| SCHEMBL3858172 | 0.76 | MEN1 (0.50) | HTR2ADRD2LMNAHTTMAPT | |
| SCHEMBL16026545 | 0.76 | PKM (0.74) | DRD2DRD3LMNARAB9AAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2234992-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | claimed |
| US-20090281087-A1 | Compounds II | BIOVITRUM AB (SE) | 2009-11-12 | — | — | US | claimed |
| WO-2009071668-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | claimed |
| EP-2234992-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2012-02-22 | — | — | EP | disclosed |
| US-8093248-B2 | Compounds useful for the treatment of conditions associated with weight gain | ASTRAZENECA AB (PUBL) (SE) | 2012-01-10 | — | — | US | disclosed |
| EP-2234992-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| US-20090281087-A1 | Compounds II | BIOVITRUM AB (SE) | 2009-11-12 | — | — | US | disclosed |
| WO-2009071668-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | disclosed |
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | HRH3, HRH1, HRH4 | HTR1A 6/4885HTR1D 5/4885HTR1B 12/4885 |
| US-20090281087-A1 | Compounds II | GPR119, FABP4, LIPC | HTR1A 1680/4885HTR1D 2160/4885HTR1B 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.